Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 4.09
(1.11%)
SEK 4.09
(1.11%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 700 Thousand SEK | 16.67% |
| 2022 | 600 Thousand SEK | -13.54% |
| 2021 | 694 Thousand SEK | -77.88% |
| 2020 | 3.13 Million SEK | 313799900.0% |
| 2019 | 1.00 SEK | -100.0% |
| 2018 | 2.09 Million SEK | 209199900.0% |
| 2017 | 1.00 SEK | 100.0% |
| 2016 | -1.6 Million SEK | -66.36% |
| 2015 | -963 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 400 Thousand SEK | -42.86% |
| 2024 Q2 | 1 Million SEK | 150.0% |
| 2023 Q1 | 400 Thousand SEK | -33.33% |
| 2023 Q3 | 400 Thousand SEK | 300.0% |
| 2023 Q2 | 100 Thousand SEK | -75.0% |
| 2023 Q4 | 700 Thousand SEK | 75.0% |
| 2023 FY | 700 Thousand SEK | 16.67% |
| 2022 Q3 | 800 Thousand SEK | 246.32% |
| 2022 FY | 600 Thousand SEK | -13.54% |
| 2022 Q4 | 600 Thousand SEK | -25.0% |
| 2022 Q1 | 440 Thousand SEK | -36.6% |
| 2022 Q2 | 231 Thousand SEK | -47.5% |
| 2021 Q1 | 2.07 Million SEK | -33.91% |
| 2021 Q3 | 964 Thousand SEK | -41.11% |
| 2021 FY | 694 Thousand SEK | -77.88% |
| 2021 Q4 | 694 Thousand SEK | -28.01% |
| 2021 Q2 | 1.63 Million SEK | -21.07% |
| 2020 FY | 3.13 Million SEK | 313799900.0% |
| 2020 Q3 | 1.00 SEK | 0.0% |
| 2020 Q4 | 3.13 Million SEK | 313799900.0% |
| 2020 Q2 | 1.00 SEK | 0.0% |
| 2020 Q1 | 1.00 SEK | 0.0% |
| 2019 Q1 | 1.00 SEK | -100.0% |
| 2019 FY | 1.00 SEK | -100.0% |
| 2019 Q4 | 1.00 SEK | -100.0% |
| 2019 Q3 | 2.5 Million SEK | -3.55% |
| 2019 Q2 | 2.59 Million SEK | 259199900.0% |
| 2018 Q4 | 2.71 Million SEK | -24.53% |
| 2018 FY | 2.09 Million SEK | 209199900.0% |
| 2018 Q3 | 3.59 Million SEK | 359899900.0% |
| 2018 Q2 | 1.00 SEK | 100.0% |
| 2018 Q1 | -730 Thousand SEK | -73000100.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | 1.00 SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | 1.00 SEK | 100.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | -1.6 Million SEK | -66.36% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | -963 Thousand SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 96.573% |
| Camurus AB (publ) | 100.95 Million SEK | 99.307% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -28.385% |
| Simris Alg AB (publ) | 1.09 Million SEK | 35.839% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 256.604% |
| Active Biotech AB (publ) | -2500.00 SEK | 28100.0% |
| Amniotics AB (publ) | 534 Thousand SEK | -31.086% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 82.647% |
| CombiGene AB (publ) | -1.79 Million SEK | 138.911% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 97.089% |
| Genovis AB (publ.) | 14.9 Million SEK | 95.304% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 47206.326% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Intervacc AB (publ) | 10.48 Million SEK | 93.323% |
| Kancera AB (publ) | -1950.00 SEK | 35997.436% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 143.05% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 98.013% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 181.112% |
| Saniona AB (publ) | 1.00 SEK | -69999900.0% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 99.345% |
| Xintela AB (publ) | 398 Thousand SEK | -75.879% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 98.401% |
| Ziccum AB (publ) | -4.18 Million SEK | 116.71% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -34999900.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 109.809% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 118.149% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -69900.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 92.281% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 77.778% |
| Biovica International AB (publ) | 2.19 Million SEK | 68.167% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -69999900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 66.346% |
| Abliva AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | -1000.00 SEK | 70100.0% |
| I-Tech AB | 4.28 Million SEK | 83.645% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 92.851% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 114.202% |
| Nanologica AB (publ) | 2.97 Million SEK | 76.455% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 94.09% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 317.97% |
| Alzinova AB (publ) | -3.27 Million SEK | 121.354% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 71.134% |
| Pila Pharma AB (publ) | 1.00 SEK | -69999900.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 31.907% |